Steatotic Liver Disease
22 September 2026, 17:00 CEST
Moderator ~ Dr. Mar Pérez-Peña
Head of Radiology Department at Alvarez-Buylla Hospital . Mieres. Asturias. Spain
MODERATOR
Dr. Mar Pérez-Peña
-
Head of Radiology Department at Alvarez-Buylla Hospital . Mieres. Asturias. Spain
-
Member of the Publications Committee of WFSUMB
-
Past member of the Publications Committee of EFSUMB
-
Member of the board of directors of Spanish Society of Ultrasound SEUS
-
Member of SERAM (Spanish Society of Radiology)
-
Multiple scientific presentations at conferences and meetings and hands-on workshops on US
-
Organizer of several radiology courses mainly in the field of US and Management and Quality
SPEAKER
Annalisa Berzigotti
Annalisa Berzigotti is Full Professor of Clinical Hepatology at the University of Berne and Chief of Hepatology and Co-Director of the Department of Visceral Surgery and Medicine of the Inselspital, University Hospital of Berne, Switzerland.
She earned her medical degree and completed her residency in Bologna, Italy, and further specialized in liver disease research and clinical practice at the Hepatic Hemodynamic Laboratory of the Liver Unit, Hospital Clinic, University of Barcelona, Spain.
Her primary interests include the invasive and non-invasive assessment and management of chronic liver disease and portal hypertension. She has authored/co-authored over 350 peer-reviewed publications on the clinical and translational aspects of liver disease.
Dr. Berzigotti has been a member of the Governing Board of the European Association for the Study of the Liver (EASL) in 2016-2019, and liver representative on the Council of United European Gastroenterology (UEG) in 2022-2025. She is Vice Chair of the Baveno Cooperation, an EASL consortium devoted to advance knowledge and practice in portal hypertension. She also serves as Deputy Editor of the Journal of Hepatology for clinical science and is member of the governing board of the Swiss Association for the Study of the Liver (SASL).
Her work has been recognized with the Stern-Gattiker Prize (Switzerland, 2018), the Lucie Bolte Prize (Germany, 2021), and the EASL Community Award (2025).
In 2025, she delivered the Jean-Pierre Benhamou Clinical State of the Art Lecture at the EASL Congress, entitled “The Promise and Pitfalls of Non-Invasive Testing.”
Steatotic Liver Disease in Clinical Practice: What Really Matters?
Learning objectives:
- Explain the current classification of steatotic liver disease
- Recognize the key clinical aspects and complications of steatotic liver disease relevant for patient management
- Introduce the practical diagnostic algorithms for the evaluation of patients with suspected steatotic liver disease, as per the major guidelines in the field (EASL/AASLD/APASL)
SPEAKER
Prof. Alina Popescu, MD, PhD
Prof. Alina Popescu is Professor of Gastroenterology and Hepatology at the Department of Gastroenterology and Hepatology, Center for Advanced Research in Gastroenterology and Hepatology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
She is also the Head of the Department of Gastroenterology and Hepatology of the “Pius Branzeu” Emergency County Clinical Hospital Timisoara, senior attendant of Gastroenterology and Internal Medicine, an expert in general ultrasonography according to the multilevel classification of SRUMB.
Currently she is the Treasurer of EFSUMB (European Federation of Societies for Ultrasound in Medicine and Biology), member of the Executive Bureau of this Society, Editor of the European Journal of Ultrasound and member of the WFUMB Publication Committee. She was President of the Romanian Society of Ultrasound in Medicine and Biology (SRUMB) for 2020-2022, former member of the Education and Professional Standards Committee of EFSUMB and of the World Federation of Ultrasound in Medicine and Biology (WFUMB) Student Education Committee.
She is the Secretary of the WFUMB Center of Education (COE) Timișoara and co-director of the EFSUMB Ultrasound Learning Center Timișoara.
Diagnosis - B-mode ultrasound
Learning Objectives:
- To identify key sonographic signs of steatotic liver disease, including parenchymal hyperechogenicity and deep attenuation.
- To differentiate between mild, moderate, and severe hepatic steatosis using B-Mode subjective criteria.
- To evaluate the diagnostic advantages and limitations of standard B-Mode imaging compared to advanced quantitative ultrasound techniques.
SPEAKER
Dr. Giovanna Ferraioli
Dr. Ferraioli is a researcher at Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia (Italy).
Her research focuses on the use of multiparametric ultrasound for the evaluation of diffuse liver disease. She is member of the Executive Board of the World Federation for Ultrasound in Medicine and Biology (WFUMB), Chair of the WFUMB Publication Committee and has chaired the WFUMB Steering Committee for “Multiparametric Ultrasound: Update to WFUMB 2018 elastography guidelines and consensus on fat quantification”. She is co-chair of the attenuation working group of the AIUM-RSNA QIBA Pulse Echo Quantitative Ultrasound (PEQUS) Biomarker Committee and member of the ACR LIRADS Quantitative Imaging Work Group. Dr. Ferraioli has delivered lectures worldwide. She has substantially contributed to guidelines on liver shear wave elastography and liver fat quantification with US-based algorithms.
Diagnosis - Quantitative ultrasound
Learning Objectives:
- Understand the fundamental principles of quantitative ultrasound in medical diagnostics.
- Identify the key techniques and parameters used in quantitative ultrasound imaging.
- Learn how to measure the ultrasound attenuation coefficient for liver fat quantification and identify possible confounding factors.
SPEAKER
Vincent Wong
Vincent Wong holds the position of Mok Hing Yiu Professor of Medicine and serves as the Head (Academic) of the Division of Gastroenterology and Hepatology at The Chinese University of Hong Kong. His research primarily revolves around steatotic liver disease and liver fibrosis, with a particular focus on the development and application of non-invasive tests for screening, diagnosis and prognostication. Notably, he contributed to the writing committee responsible for formulating the guidelines of the Asian Pacific Association for the Study of the Liver, American Gastroenterological Association and the European Association for the Study of the Liver. He has authored more than 700 publications in international medical journals. His h-index is 142 as of November 2025 by Google Scholar. He holds the position of associate editor for the Journal of Hepatology and serves as an editorial board member for renowned medical journals such as Gastroenterology, JHEP Reports, and Clinical and Molecular Hepatology. He was the president of the Hong Kong Association for the Study of Liver Diseases from 2015 to 2017 and the Chairman of the Specialty Board of Gastroenterology and Hepatology at the Hong Kong College of Physicians from 2022 to 2025. He has been honoured with research awards from esteemed organizations such as the Asian Pacific Association for the Study of the Liver, Asian Pacific Digestive Week Federation, British Society of Gastroenterology, Hong Kong College of Physicians, the Health Bureau of the Hong Kong SAR Government, and the Ministry of Science and Technology and the Ministry of Education of China.Department of Medicine and Therapeutics, The Chinese University of Hong Kong.
Treatment of MASLD
Learning Objectives:
- To understand the mechanisms of action, efficacy, and limitations of currently approved treatments for MASH
- To learn the role of imaging biomarkers in patient selection for treatment and response assessment
- To understand the main classes of drugs in late phase development
